Webinars

View On-Demand Webinars That Demonstrate the Clinical Benefit and Patient Impact of DEFINITY®

A Clearer Echo: Improve Your Lab Efficiency and Patient Outcomes

Martin E. Goldman, MD, discusses the impact of DEFINITY® in COVID-19 patients, and Paul Bhella, MD, FASE, FAHA, FACC explores clinical case studies and data illustrating the benefits of DEFINITY^® while reviewing ASE guidelines

Enhanced Optimization Techniques for Contrast Echo

Steven Walling, BS, RCS, RDCS, FASE, presents "Enhanced Optimization Techniques for Contrast Echo"

Contrast Echo: See in High DEF(INITY)™, Experience the Impact

Jonathan R. Lindner, MD, Lissa Sugeng, MD, MPH, and Rajesh Janardhanan, MD present the Lantheus 2015 ASE Science & Technology Theater Program

Are You Optimizing the Use of Contrast Echocardiography? A Case-Based Discussion

Anita M. Kelsey, MD and Steven Walling, RDCS explore 2 cases to illustrate the importance of teamwork, operational efficiency, and the appropriate use of DEFINITY® in achieving quality echocardiographic imaging

Case-Based Review of Clinical Safety: Contrast Echocardiography in the Acute Critical Care Setting

Eyal Herzog, MD shows how the appropriate use of DEFINITY® assisted in achieving quality diagnostic imaging in critically ill patients with suboptimal echocardiograms

Enhanced Echocardiography: It's What You Don't See That Matters

Ben Lin, MD, Theresa Green, RDCS, and Sean McMahon, MD present the Lantheus 2019 ASE Science & Technology Theater Program

COVID-19: Realizing the Value of Enhanced Echo

Smadar Kort, MD, FACC, FASE, FAHA, presents “Cardiovascular Complications of COVID-19” and Susan Dillon, RDCS, FASE, presents “Echo Lab Efficiencies Expedite Patient Management Decisions”

Contrast Echo Guidelines: See the Impact

Paul Braum, BS, RVT, RDCS, RVS, FASE, presents "Contrast Echo Guidelines: See the Impact"

Clinical Case Reviews: The Impact of Contrast Echocardiography

Amr E. Abbas, MD and Judy Malone, BS, RDCS explore clinical case studies illustrating how an efficient implementation of DEFINITY® across clinical settings may impact diagnostic outcomes and patient management decisions

Who Benefits From the Use of Contrast Echocardiography?

Vincent Sorrell, MD, Michael Rampoldi ACS, and Kirsten Tolstrup, MD highlight the advantages contrast echocardiography has over unenhanced echo in diagnostic outcomes, patient management, and cost effectiveness

Enhanced Echo at the Point of Care: Impact on Quality and Outcomes

Jayanta T. Mukherjee, MD and Daniel F. Skully, MD share their experiences and insights on the diagnostic impact and clinical value of DEFINITY® at the point of care, highlighting the impact DEFINITY® has on the critically ill

Are You Really Improving Quality with Contrast Echocardiography?

Paul S. Bhella, MD, Paul Braum, BS, RDCS, and Joan S. Crawford, DO present the Lantheus 2016 ASE Science & Technology Theater Program

Achieving Workflow Efficiency With Contrast Echocardiography: Best Practices and Case-Based Discussion

Bret Rogers, MD and Chad Bousanti, RCS share institutional experiences establishing efficient processes and logistics for effective use of DEFINITY®

The Diagnostic Advantage of Contrast Echocardiography

Anita M. Kelsey, MD, Margaret M. Park, BS, ACS, and Kevin Wei, MD present the Lantheus 2017 ASE Science & Technology Theater Program

The Value of Contrast Echocardiography Across Multiple Care Settings

Dennis Mihalatos, MD and Robert W. Biederman, MD lead a case-based discussion highlighting how DEFINITY® impacts diagnostic outcomes and patient management across multiple patient care settings

Improving Quality and Efficiency in Echocardiography

Omar Husseini, MD, presents “Efficiently implement the appropriate use of DEFINITY® within your institution” and Gina Conigliaro-Brito, MHA, RDCS, RCS, RVS, presents “Establishing a Sonographer Contrast Administration Protocol”

The Impact of Ultrasound Contrast on Patient Care

Kevin Wei, MD, FACC, FASE, Professor of Medicine Cardiovascular Institute Oregon Health & Sciences University, presents "The Impact of Ultrasound Contrast on Patient Care"

Improve Patient Management by Selecting the Appropriate Echo Contrast Agent: A Case-Based Discussion

Kamran Shaikh, MD and Andy Isaacks, RDCS use actual cases to highlight the important role DEFINITY® has in establishing quality-driven echocardiography and improving patient outcomes

Quality Performance of Using DEFINITY® in the Echocardiography Lab

Michael Rampoldi, ACS, RDCS, RVT, FASE, presents "Quality Performance of Using DEFINITY® in the Echocardiography Lab"

COVID-19: Clinical Experience with DEFINITY® from the Front Line in NYC

Martin Goldman, MD, Lori Croft, MD, and Samantha Buckley, RDCS share their experience treating patients and provide insight into the use of DEFINITY® during the COVID-19 pandemic

The Benefits of Contrast on Patient Management

Vincent L. Sorrell, MD, FACC, FASE, presents "The Benefits of Contrast on Patient Management"

The Significance of Accurate Endocardial Border Delineation

Theresa Green, RDCS, Echocardiography Advanced Coordinator Piedmont Hospital, presents "The Significance of Accurate Endocardial Border Delineation"

Modern-Day Contrast Themes

William A. Zoghbi, MD, Michael L. Main, MD, and Lissa Sugeng, MD, MPH present the Lantheus 2014 ASE Science & Technology Theater Program

INDICATIONS

DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.

Assess all patients for the presence of any condition that precludes DEFINITY® administration [see Contraindications (4)].
Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension

INDICATIONS

CONTRAINDICATIONS

DEFINITY® is contraindicated in patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG) [see Warnings and Precautions (5.2) and Description (11)].

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Assess all patients for the presence of any condition that precludes DEFINITY® administration [see Contraindications (4)].
Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

In postmarketing use, rare but serious cardiopulmonary or hypersensitivity reactions have been reported during or shortly following perflutren and PEG-containing microsphere administration [see Adverse Reactions (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions and/or with pre-existing PEG hypersensitivity [see Adverse Reactions (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying conditions.

Patients with sickle cell disease may be at higher risk of painful crisis and DEFINITY® should be administered with caution.

Please see accompanying full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.

Customer Service 1.800.299.3431

BACK TO
TOP